Identification and evaluation of magnolol and chrysophanol as the principle protein tyrosine phosphatase-1B inhibitory compounds in a Kampo medicine, Masiningan

Onoda, Toshihisa; Li, Wei; Sasaki, Tatsunori; Miyake, Megumi; Higai, Koji; Koike, Kazuo

doi:10.1016/j.jep.2016.03.063

Cited by 24 publications

(17 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In‐vivo research showed that the combination of chrysophanol and emodin could inhibit PTP1B activity and strongly enhanced insulin sensitivity of HFD (high‐fat diet)‐fed mice . Subsequent research showed that chrysophanol was a competitive PTP1B inhibitor . In addition, chrysophanol was an excellent plasminogen activator inhibitor‐1 (PAI‐1 inhibitor) (IC 50 = 1.06 μ m ) .…”

Section: Pharmacologymentioning

confidence: 99%

“…[59] Subsequent research showed that chrysophanol was a competitive PTP1B inhibitor. [60] In addition, chrysophanol was an excellent plasminogen activator inhibitor-1 (PAI-1 inhibitor) (IC 50 = 1.06 lM). [61] Later, Lian et al found that chrysophanol could activate nuclear factor erythroid 2-related factor 2 (Nrf2), which reduced metabolic disorders and heart damage caused by diabetes.…”

Section: Regulating Blood Lipid Activitymentioning

confidence: 99%

See 1 more Smart Citation

Chrysophanol: a review of its pharmacology, toxicity and pharmacokinetics

Xie

Tang

Song

et al. 2019

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

Objective Chrysophanol is a natural anthraquinone, also known as chrysophanic acid and 1,8‐dihydroxy‐3‐methyl‐anthraquinone. It has been widely used in the food and pharmaceutical fields. This review is intended to provide a comprehensive overview of the pharmacology, toxicity and pharmacokinetic researches of chrysophanol. Key finding Information on chrysophanol was collected from the Internet database PubMed, Elsevier, ResearchGate, Web of Science, Wiley Online Library and Europe PM using a combination of keywords including ‘pharmacology’, ‘toxicology’ and ‘pharmacokinetics’. The literature we collected included from January 2010 to June 2019. Chrysophanol has a wide spectrum of pharmacological effects, including anticancer, antioxidation, neuroprotection, antibacterial and antiviral, and regulating blood lipids. However, chrysophanol has obvious hepatotoxicity and nephrotoxicity, and pharmacokinetics indicate that the use of chrysophanol in combination with other drugs can reduce toxicity and enhance efficacy. Summary Chrysophanol can be used in many diseases. Future research directions include how the concentration of chrysophanol affects pharmacological effects and toxicity; the mechanism of synergy between chrysophanol and other drugs.

show abstract

Section: Pharmacologymentioning

confidence: 99%

Section: Regulating Blood Lipid Activitymentioning

confidence: 99%

Chrysophanol: a review of its pharmacology, toxicity and pharmacokinetics

Xie

Tang

Song

et al. 2019

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

show abstract

“…To test docking interactions, we followed the method of Onoda et al 22 with some modications. The ligand library comprised 400 di-peptides and 6138 tri-peptides generated by degradation of egg proteins (Tables 1 and S1 †), including egg white and egg yolk proteins, and proteins of fertilized eggs.…”

Section: Docking Experimentsmentioning

confidence: 99%

Direct inhibition of Keap1–Nrf2 interaction by egg-derived peptides DKK and DDW revealed by molecular docking and fluorescence polarization

Liu

Nie

et al. 2017

RSC Adv.

View full text Add to dashboard Cite

show abstract

“…Chrysophanol glucosides, chrysophanol‐8‐O‐β‐D‐glucopyranoside, chrysophanol triglucoside, and chrysophanol tetraglucoside from S. obtusifolia inhibited PTP 1B activity with IC 50 values of 8.8, 80.17, and 103.89 μM, respectively (Jung et al, ). Similarly, Onoda et al () have reported that chrysophanol isolated from Masiningan extract, a traditional herbal medicine consisting of Cannabis sativa Linne, Paeonia lactiflora Pallas, Citrus aurantium Linne, Magnolia officinalis Rehd. et Wils., R. officinale Baillon, and Prunus armeniaca Linne inhibited PTP 1B activity (IC 50 :12.3 μM).…”

Section: Resultsmentioning

confidence: 95%

Antidiabetic potential of anthraquinones: A review

Mohammed

Ibrahim

Tajuddeen

et al. 2019

Phytotherapy Research

View full text Add to dashboard Cite

The present study was designed to review the antidiabetic potential of anthraquinones (AQs) with emphasis on the extent of blood glucose reduction, the half maximal inhibitory concentration values (in vitro studies), the proposed mechanisms of action, and the structure activity relationship studies. We sourced relevant data from the major scientific databases (Pubmed, Science Direct, Medline, and Google Scholar). According to our search, 25 AQs have shown variable antidiabetic potential, whereas one AQ (morindone‐6‐O‐β‐D‐primeveroside) showed no blood glucose‐lowering ability. Emodin and rhein showed the most promising antidiabetic potential in various models. The proposed mechanisms of antidiabetic action include upregulation of insulin receptor substrates‐1, phosphoinositide‐3‐kinase, and Akt‐ser473 expression and elevation of glucagon‐like peptide‐1 level in diabetic animal models linked to the potent protein tyrosine phosphatase 1B and dipeptidyl peptidase‐4 inhibitions. In addition, activation of peroxisome proliferator‐activated receptors gamma and inhibition of α‐glucosidase activity are other possible targets proposed as the mechanism of AQs antidiabetic action. The position and the number of hydroxyl group showed great influence on the overall antidiabetic potential of AQs. AQs hold promising antidiabetic activity despite scanty information. We hope that the present study will serve as a template to further explore the antidiabetic potential of AQs and subsequent antidiabetic drug development.

show abstract

Identification and evaluation of magnolol and chrysophanol as the principle protein tyrosine phosphatase-1B inhibitory compounds in a Kampo medicine, Masiningan

Cited by 24 publications

References 25 publications

Chrysophanol: a review of its pharmacology, toxicity and pharmacokinetics

Chrysophanol: a review of its pharmacology, toxicity and pharmacokinetics

Direct inhibition of Keap1–Nrf2 interaction by egg-derived peptides DKK and DDW revealed by molecular docking and fluorescence polarization

Antidiabetic potential of anthraquinones: A review

Contact Info

Product

Resources

About